Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
A phase 2 trial of Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine and Inavolisib in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study is a phase 2 interventional study registered as NCT04589845 by Hoffmann-La Roche, with 920 participants enrolled, started 2021-01-18 and due to reach its primary completion in 2032-09-25. Interventions recorded: Entrectinib, Alectinib, Atezolizumab, Ipatasertib, Trastuzumab emtansine and Inavolisib.
Similar pages
not linked directly; found by shared links- TrialA Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Shares Trastuzumab emtansine, Flatiron Health (Roche), Atezolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialTo Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
Shares Inavolisib, Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Shares Trastuzumab emtansine, Flatiron Health (Roche), Atezolizumab and the tag pipeline.
- TrialA Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Shares Inavolisib, Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Shares Ipatasertib, Flatiron Health (Roche), Atezolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Shares Ipatasertib, Inavolisib, Flatiron Health (Roche) and the tag pipeline.
- TrialA Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Shares Inavolisib, Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Shares Flatiron Health (Roche), Atezolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.